Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant Sciences
Biotech
Roivant's Hemavant bet winds down after cutting ex-Eisai drug
Roivant’s Hemavant has discontinued development of its only asset, a former Eisai drug dubbed RVT-2001 that was being studied in patients with MDS.
Gabrielle Masson
Feb 13, 2024 2:01pm
BMS signs $674M biobucks pact with VantAI for molecular glues
Feb 13, 2024 11:00am
Genevant secures $114M deal with Tome to develop liver therapy
Jan 16, 2024 10:11am
Roivant ends longshot lupus program after phase 2 fail
Nov 27, 2023 9:48am
Lokavant debuts study planning platform to aid site selection
Aug 31, 2023 8:03am
Gritstone taps Genevant to power up infectious disease vaccines
Aug 15, 2023 10:00am